In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15

Melanoma Research

Volumn 25, Issue 1, 2015, Pages 22-34

  Vuletić, Ana M ^a   Jovanić, Irena P ^a   Jurišić, Vladimir B ^e   Milovanović, Zorka M ^b   Nikolić, Srdan S ^a   Tanić, Nikola T ^c   Konjević, Gordana M ^a,d  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^b Department of Pathology ^*  (Serbia)

^c Department of Neurobiology Institute for Biological Research 'Sini a Stankovi   (Serbia)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

CD16; cytotoxicity; interleukin 15; interleukin 2; killer cell immunoglobulin like receptor; lymph nodes; melanoma; natural killer cells; NKG2D; perforin

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; PERFORIN; CD69 ANTIGEN; LECTIN; LEUKOCYTE ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; T LYMPHOCYTE ANTIGEN;

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DISEASE SEVERITY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPH NODE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; MONONUCLEAR CELL; NATURAL KILLER CELL; PHENOTYPE; PROTEIN EXPRESSION; PURIFICATION; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOTHERAPY; K562 CELL LINE; METABOLISM; METASTASIS; PATHOLOGY; PROCEDURES; SKIN TUMOR; TIME;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MELANOMA; NEOPLASM METASTASIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SKIN NEOPLASMS; TIME FACTORS;

EID: 84920264251     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000126     Document Type: Article

References (48)

1. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J 2010; 16:392-398.
2. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-49.
3. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-640.
4. Eissens DN, Spanholtz J, van der Meer A, van Cranenbroek B, Dolstra H, Kwekkeboom J, et al. Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS One 2012; 7:e30930.
5. Konjevic G, Mirjacic Martinovic K, Vuletic A, Jovic V, Jurisic V, Babovic N, et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007; 24:1-11.
6. Konjevic G, Jurisic V, Jovic V, Vuletic A, Mirjacic Martinovic K, Radenkovic S, et al. Investigation of NK cell function and their modulation in different malignancies. Immunol Res 2012; 52 (1-2):139-156.
7. Carrega P, Pezzino G, Queirolo P, Bonaccorsi I, Falco M, Vita G, et al. Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells. PLoS One 2009; 4:e8132.
8. Vuletic A, Juriic V, Jovanic I, Milovanovic Z, Nikolic S, Konjevic G. Distribution of several activating and inhibitory receptors on CD3(-)CD56(+) NK cells in regional lymph nodes of melanoma patients. J Surg Res 2013; 183:860-868.
9. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors 2010; 36:274-288.
10. Meazza R, Azzarone B, Orengo AM, Ferrini S. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol 2011; 2011:861920.
11. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13-25.
12. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33:35-41.
13. Zafirova B, Wensveen FM, Gulin M, Polic B. Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 2011; 68:3519-3529.
14. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell 2010; 142:847-856.
15. Campoli M, Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol 2011; 33:321-334.
16. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011; 132:315-325.
17. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique subpopulations of CD56 + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001; 166:6477-6482.
18. - killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 2007; 178:4947-4955.
19. Moretta L. Dissecting CD56dim human NK cells. Blood 2010; 116:3689-3691.
20. Chen S, Kawashima H, Lowe JB, Lanier LL, Fukuda M. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J Exp Med 2005; 202:1679-1689.
21. Jackson A, Warner N. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose N, Friedman H, Fahey J, editors. Manual of clinical laboratory immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986. pp. 226-235.
22. Brown RL, Ortaldo JR, Griffith RL, Blanca I, Rabin H. The proliferation and function of human mononuclear leukocytes and natural killer cells in serum-free medium. J Immunol Methods 1985; 81:207-214.
23. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294:15-22.
24. Seidel MG, Freissmuth M, Pehamberger H, Micksche M. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2. Naunyn Schmiedebergs Arch Pharmacol 1998; 358:382-389.
25. Sabry M, Lowdell MW. Tumor-primed NK cells: waiting for the green light. Front Immunol 2013; 4:408.
26. Konjevic G, Mirjacic Martinovic K, Vuletic A, Babovic N. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients. Melanoma Res 2010; 20:459-467.
27. Zhang C, Zhang J, Niu J, Zhang J, Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008; 42:128-136.
28. Fernández L, Portugal R, Valentín J, Martín R, Maxwell H, González-Vicent M, et al. In vitro natural killer cell immunotherapy for medulloblastoma. Front Oncol 2013; 3:94.
29. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 2008; 45:3917-3925.
30. Buddingh EP, Schilham MW, Ruslan SE, Berghuis D, Szuhai K, Suurmond J, et al. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother 2011; 60:575-586.
31. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172:1455-1462.
32. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101:3052-3057.
33. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, et al. Acquisition of murine NK cell cytotoxicity requires the translation of a preexisting pool of granzyme B and perforin mRNAs. Immunity 2007; 26:798-811.
34. Uellner R, Zvelebil MJ, Hopkins J, Jones J, MacDougall LK, Morgan BP, et al. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J 1997; 16:7287-7296.
35. Pillet AH, Thèze J, Rose T. Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes. Hum Immunol 2011; 72:1013-1017.
36. Clausen J, Vergeiner B, Enk M, Petzer AL, Gastl G, Gunsilius E. CD69 is a useful marker for cytotoxic activity of NK cells. Immunobiology 2003; 207:85-93.
37. Decot V, Voillard L, Latger-Cannard V, Aissi-Rothe L, Perrier P, Stoltz JF, et al. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol 2010; 38:351-362.
38. Park YP, Choi SC, Kiesler P, Gil-Krzewska A, Borrego F, Weck J, et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood 2011; 118:3019-3027.
39. Cichocki F, Hanson RJ, Lenvik T, Pitt M, McCullar V, Li H, et al. The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element. Blood 2009; 113:3245-3253.
40. Juelke K, Killig M, Thiel A, Dong J, Romagnani C. Education of hyporesponsive NK cells by cytokines. Eur J Immunol 2009; 39:2548-2555.
41. Guia S, Jaeger BN, Piatek S, Mailfert S, Trombik T, Fenis A, et al. Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. Sci Signal 2011; 4:ra21.
42. Tomova R, Pomakov J, Jacobs JJ, Adjarov D, Popova S, Altankova I, et al. Changes in cytokine profile during local IL-2 therapy in cancer patients. Anticancer Res 2006; 26 (3A):2037-2047.
43. Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Jemma C, Giovarelli M, et al. Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer. Head Neck 1991; 13:125-131.
44. Musiani P, De Campora E, Valitutti S, Castellino F, Calearo C, Cortesina G, et al. Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. J Biol Response Mod 1989; 8:571-578.
45. Miller JS. Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program 2013; 2013:247-253.
46. Besser MJ, Shoham T, Harari-Steinberg O, Zabari N, Ortenberg R, Yakirevitch A, et al. Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One 2013; 8:e57922.
47. Zheng R, Kjaergaard J, Lee WT, Cohen PA, Shu S. Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. Cancer Treat Res 2007; 135:223-237.
48. Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, Mazouz-Dorval S, et al. Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res 2014; 74:81-92.